All In Biotech

Investigational drug · Phase 3

TS-172 20~

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hyperphosphatemia Patients on Hemodialysis, Hyperphosphatemia Patients on Peritoneal Dialysis.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

3 still active

All registered trials

11

Any phase or sponsor naming "TS-172 20~"

First trial start

2025

Jan 6, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TS-172 20~", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hyperphosphatemia Patients on Hemodialysis
  • Hyperphosphatemia Patients on Peritoneal Dialysis

Approved drugs for the same conditions: Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "TS-172 20~" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Hyperphosphatemia Patients on Hemodialysis

  • TS-172Phase 32 trials

    Taisho Pharmaceutical Co., Ltd. · Hyperphosphatemia Patients on Hemodialysis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.